$PYPD
PolyPid Ltd Stock $pypd

$pypd Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024020424 Filed on March 06, 2024

Income Statement

Concept	2023 Q4	2023
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.411M	$6.719M
YoY Change	-27.9%	-38.36%
% of Gross Profit
Research & Development	$4.588M	$16.15M
YoY Change	-1.44%	-42.31%
% of Gross Profit
Depreciation & Amortization	$912.0K	$1.822M
YoY Change		5.87%
% of Gross Profit
Operating Expenses	$5.999M	$22.87M
YoY Change	-9.27%	-18.3%
Operating Profit		-$22.87M
YoY Change		-41.2%
Interest Expense	-$348.0K	-$929.0K
YoY Change	-448.0%	-216.13%
% of Operating Profit
Other Income/Expense, Net		-$929.0K
YoY Change		72.04%
Pretax Income	-$6.347M	-$23.80M
YoY Change	-2.53%	-160.16%
Income Tax	$9.000K	$69.00K
% Of Pretax Income
Net Earnings	-$6.356M	-$23.87M
YoY Change	-3.21%	-39.67%
Net Earnings / Revenue
Basic Earnings Per Share		$16.99
Diluted Earnings Per Share	-$3.84	-$16.99
COMMON SHARES
Basic Shares Outstanding	1.654M shares	1.404M shares
Diluted Shares Outstanding		1.421M shares

Balance Sheet

Concept	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.309M	$5.309M
YoY Change	-57.85%	-57.85%
Cash & Equivalents	$5.309M	$5.309M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$758.0K	$758.0K
YoY Change	-52.63%	-44.31%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$6.067M	$6.067M
YoY Change	-57.26%	-57.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.218M	$9.218M
YoY Change	-0.31%	-21.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$87.00K	$87.00K
YoY Change	-12.12%	-12.12%
Total Long-Term Assets	$9.305M	$9.305M
YoY Change	-20.99%	-20.99%
TOTAL ASSETS
Total Short-Term Assets	$6.067M	$6.067M
Total Long-Term Assets	$9.305M	$9.305M
Total Assets	$15.37M	$15.37M
YoY Change	-40.81%	-40.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$772.0K	$772.0K
YoY Change	-32.34%	-32.34%
Accrued Expenses	$2.511M	$2.511M
YoY Change	101.52%	-25.53%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$4.003M	$4.003M
YoY Change	-0.52%
Total Short-Term Liabilities	$7.286M	$7.286M
YoY Change	-14.81%	-14.81%
LONG-TERM LIABILITIES
Long-Term Debt	$6.379M	$6.379M
YoY Change	-15.78%	-15.78%
Other Long-Term Liabilities	$3.803M	$3.803M
YoY Change	23668.75%	-5.28%
Total Long-Term Liabilities	$10.18M	$10.18M
YoY Change	63537.5%	-12.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.286M	$7.286M
Total Long-Term Liabilities	$10.18M	$10.18M
Total Liabilities	$17.47M	$17.47M
YoY Change	103.85%	-13.28%
SHAREHOLDERS EQUITY
Retained Earnings	-$238.3M
YoY Change	11.13%
Common Stock	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.096M	-$2.096M
YoY Change
Total Liabilities & Shareholders Equity	$15.37M	$15.37M
YoY Change	-40.81%	-40.81%

Cashflow Statement

Concept	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$6.356M	-$23.87M
YoY Change	-3.21%	-39.67%
Depreciation, Depletion And Amortization	$912.0K	$1.822M
YoY Change		5.87%
Cash From Operating Activities	-$8.956M	-$17.24M
YoY Change		-49.77%
INVESTING ACTIVITIES
Capital Expenditures	-$4.000K	$196.0K
YoY Change		-88.91%
Acquisitions
YoY Change
Other Investing Activities	$11.67M	$4.000M
YoY Change		-78.19%
Cash From Investing Activities	$11.66M	$3.804M
YoY Change		-77.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$2.618M
YoY Change		551.24%
Cash From Financing Activities	-1.004M	$9.976M
YoY Change		-39.27%
NET CHANGE
Cash From Operating Activities	-8.956M	-$17.24M
Cash From Investing Activities	11.66M	$3.804M
Cash From Financing Activities	-1.004M	$9.976M
Net Change In Cash	1.704M	-$3.456M
YoY Change		163.01%
FREE CASH FLOW
Cash From Operating Activities	-$8.956M	-$17.24M
Capital Expenditures	-$4.000K	$196.0K
Free Cash Flow	-$8.952M	-$17.43M
YoY Change		-51.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38428
CY2023	dei	Entity Registrant Name EntityRegistrantName	POLYPID LTD.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	18 Hasivim Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Petach Tikva
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	495376
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value
CY2023	dei	Trading Symbol TradingSymbol	PYPD
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1653559	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1281
CY2023	dei	Auditor Name AuditorName	KOST FORER GABBAY & KASIERER
CY2023	dei	Auditor Location AuditorLocation	Haifa, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5309000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8552000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	300000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	511000	usd
CY2022Q4	us-gaap	Deposits Assets DepositsAssets	4042000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	458000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1089000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6067000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14194000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7621000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9247000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1597000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2431000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	87000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	99000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	9305000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	11777000	usd
CY2023Q4	us-gaap	Assets Assets	15372000	usd
CY2022Q4	us-gaap	Assets Assets	25971000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4003000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4024000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1971000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2429000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	772000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1141000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	540000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	959000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7286000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8553000	usd
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	6379000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	7574000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2548000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2548000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	857000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1173000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	398000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	294000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10182000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	11589000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	107800000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	47800000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1653559	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1653559	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	669605	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	669605	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	236213000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	220273000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-238309000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-214444000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2096000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5829000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15372000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	25971000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16148000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27990000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30553000	usd
CY2023	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	1196000	usd
CY2022	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2888000	usd
CY2021	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	2983000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5523000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8010000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9609000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-22867000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-38888000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-43145000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-929000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-540000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	544000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-23796000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39428000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-42601000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	129000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23865000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-39557000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42601000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	16.99
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	61.09
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	68.27
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.93
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	61.09
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	68.27
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1404368	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	647556	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	624051	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1421308	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	647556	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	624051	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	72777000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4750000	usd
CY2021	pypd	Exercise Of Warrants ExerciseOfWarrants	632000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	402000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42601000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35960000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4307000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4423000	usd
CY2022	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	588000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	108000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-39557000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	5829000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3391000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8723000	usd
CY2023	pypd	Stock Issue During Period Value Issuance Of Prefunded Warrants Net StockIssueDuringPeriodValueIssuanceOfPrefundedWarrantsNet	3987000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	31000	usd
CY2023	pypd	Stockissue During Period Value Reclassification Of Prefunded Warrants To Liabilities StockissueDuringPeriodValueReclassificationOfPrefundedWarrantsToLiabilities	-2106000	usd
CY2023	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	1905000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23865000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2096000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23865000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-39557000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42601000	usd
CY2023	us-gaap	Depreciation Depreciation	1822000	usd
CY2022	us-gaap	Depreciation Depreciation	1721000	usd
CY2021	us-gaap	Depreciation Depreciation	1118000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-201000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1727000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-289000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3391000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4307000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4750000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-641000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1185000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-83000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	593000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2431000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-494000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	2132000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-369000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-3095000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	2221000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2548000	usd
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-481000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1416000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	2043000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17236000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34317000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32386000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	18600000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7000000	usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	8000000	usd
CY2023	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	22600000	usd
CY2022	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	25342000	usd
CY2021	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	47893000	usd
CY2021	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	340000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	196000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1767000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2653000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3804000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16575000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	36900000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	632000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	108000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	402000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8723000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4423000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	11711000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2618000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	402000	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	125000	usd
CY2023	pypd	Proceeds From Issuance Of Prefunded Warrants Net ProceedsFromIssuanceOfPrefundedWarrantsNet	3987000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	588000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9976000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16428000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1034000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-3456000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1314000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5548000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9142000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10456000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4908000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5686000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9142000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10456000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1038000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	734000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	18000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	8000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5309000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8552000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9819000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	300000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	511000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	397000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	77000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	79000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	240000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5686000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9142000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10456000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	941000	usd
CY2022	pypd	Property And Equipment Paid For In Prior Periods PropertyAndEquipmentPaidForInPriorPeriods	340000	usd
CY2021	pypd	Property And Equipment Paid For In Prior Periods PropertyAndEquipmentPaidForInPriorPeriods	395000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	241000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3528000	usd
CY2023	pypd	Credit Line Derivative CreditLineDerivative	127000	usd
CY2023	pypd	Modification Of Warrants ModificationOfWarrants	31000	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1020000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	1259000	usd
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<table cellpadding="0" cellspacing="0" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.75in; text-align: left">NOTE 1:-</td><td style="text-align: justify">GENERAL</td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">a.</td><td style="text-align: justify">PolyPid Ltd. (the “Company”) was incorporated under the laws of Israel and commenced operations on February 28, 2008. The Company is a Phase 3 biopharmaceutical company focused on developing targeted, locally administered, and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. The Company’s product candidates are designed to address unmet medical needs by delivering active pharmaceutical ingredients, or APIs, locally at predetermined release rates and durations over extended periods ranging from days to several months. The Company is initially focused on the development of its lead product candidate, D-PLEX<sub>100</sub>, which incorporates an antibiotic for the prevention of surgical site infection in bone and soft tissue. Through December 31, 2023, the Company has been primarily engaged in research and development.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company’s wholly owned subsidiaries include a subsidiary in the United States of America (the “US Subsidiary”) and a subsidiary in Romania. The US Subsidiary’s operation focuses on marketing and business development of the Company’s operation in the United States of America.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On June 30, 2020, the Company closed its initial public offering (“IPO”) whereby 143,750 Ordinary shares were sold by the Company to the public (inclusive of 18,750 Ordinary shares pursuant to the full exercise of an overallotment option granted to the underwriters). The aggregate net proceeds received by the Company from the offering were $62,757, net of underwriting discounts and other offering costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">b.</td><td style="text-align: justify">On September 18, 2023, the Company’s board of directors approved 1-for-30 reverse share split. No fractional shares were issued, and no cash or other consideration was paid as a result of the reverse share split. Instead, the Company issued one additional whole share of the post-reverse share split Ordinary share to any shareholder who otherwise would have received a fractional share as a result of the reverse share split. The amount of authorized Ordinary shares was not affected. All issued and outstanding share and per share amounts included in the accompanying consolidated financial statements have been adjusted to reflect this reverse share split for all periods presented.</td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">c.</td><td style="text-align: justify">The Company’s activities since inception have consisted of performing research and development activities. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations is dependent on future events, including, among other things, its ability to secure financing; obtain marketing approval from regulatory authorities; access potential markets; build a sustainable customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. The Company’s operations are funded by its shareholders and research and development grants and the Company intends to seek further private or public financing as well as make applications for further research and development grants for continuing its operations.</td></tr></table> <p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">In September 2022, the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX<sub>100</sub> (“SHIELD”) I Phase 3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (“SSIs”), re-interventions due to SSIs and mortality: in the Intent to Treat (“ITT”) population, the local administration of D-PLEX<sub>100</sub> and standard of care (“SoC”), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">That said, in a pre-specified subgroup ITT analysis requested by the United States (“U.S.”) Food and Drug Administration (“FDA”) of a total of 423 subjects with large incisions (>20 centimeters), the local administration of D-PLEX<sub>100 </sub>resulted in a significant reduction of 54 percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX<sub>100</sub> treatment arm (n=212).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">In November 2022, the Company provided the FDA with available data from the SHIELD I study as part of a Type D meeting request. Following positive Type D meeting communication with the FDA, which took place in January 2023, on the SHIELD I Phase 3 data, the Company now has a clear regulatory pathway towards a potential new drug application (“NDA”) submission. Based on the data, particularly the 54% reduction observed in the primary endpoint in complex surgeries in a pre-specified subgroup analysis of patients with large open incisions (p=0.0032, n=423) compared to SoC, the FDA acknowledged that the SHIELD I results may provide supportive evidence on this population and recommended that the Company conduct an additional study to support a potential NDA submission. The FDA stated that the ongoing SHIELD II study could potentially serve as such a study. The FDA also recognized that D-PLEX<sub>100</sub>’s proposed indication is for the prevention of infection and has the potential for wide use.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company resumed recruitment into the SHIELD II trial in June 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -28.35pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company expects to continue to incur substantial losses over the next several years during its clinical development phase. To fully execute its business plan, the Company will need to complete phase 3 clinical studies and certain development activities as well as manufacture the required clinical and commercial production batches in the pilot manufacturing plant. Further, the Company’s product candidates will require regulatory approval prior to commercialization and the Company will need to establish sales, marketing and logistic infrastructures. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">As of December 31, 2023, the Company had cash and cash equivalents in the total amount of $5,309. During the year ended December 31, 2023, the Company incurred a net loss of $23,865 and had negative cash flows from operating activities of $17,236. In addition, the Company had an accumulated deficit of $238,309 at December 31, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company’s future operations are highly dependent on a combination of factors, including (i) completion of all required clinical studies; (ii) the success of its research and development activities; (iii) manufacture of all required clinical and commercial production batches; (iv) marketing approval by the relevant regulatory authorities; and (v) market acceptance of the Company’s product candidates. There can be no assurance that the Company will succeed in achieving the clinical, scientific and commercial milestones as detailed above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> Based on the abovementioned, as of the approval date of these consolidated financial statements, the Company has not raised the necessary funding in order to continue its activity for a period of at least one year after the date of the filing of this annual report on Form 20-F. Therefore, these factors raise a substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that might result should the Company be unable to continue as a going concern.</p>
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company’s board of directors approved 1-for-30 reverse share split
CY2023	pypd	Description Administration DescriptionAdministration	the Company announced top-line results from the Surgical site Hospital acquired Infection prEvention with Local D-PLEX100 (“SHIELD”) I Phase 3 trial. SHIELD I did not achieve its primary endpoint of reduction in Surgical Site Infections (“SSIs”), re-interventions due to SSIs and mortality: in the Intent to Treat (“ITT”) population, the local administration of D-PLEX100 and standard of care (“SoC”), (n=485) resulted in a decrease in the primary endpoint of 23 percent compared to SoC alone (n=489) (p=0.1520).That said, in a pre-specified subgroup ITT analysis requested by the United States (“U.S.”) Food and Drug Administration (“FDA”) of a total of 423 subjects with large incisions (>20 centimeters), the local administration of D-PLEX100 resulted in a significant reduction of 54 percent in the primary endpoint, compared to SoC alone (p=0.0032). Within the first 30 days post-surgery, SSIs decreased from 9.7% in the SoC treatment arm (n=211), as compared to 4.4% in the D-PLEX100 treatment arm (n=212).In November 2022, the Company provided the FDA with available data from the SHIELD I study as part of a Type D meeting request. Following positive Type D meeting communication with the FDA, which took place in January 2023, on the SHIELD I Phase 3 data, the Company now has a clear regulatory pathway towards a potential new drug application (“NDA”) submission. Based on the data, particularly the 54% reduction observed in the primary endpoint in complex surgeries in a pre-specified subgroup analysis of patients with large open incisions (p=0.0032, n=423) compared to SoC, the FDA acknowledged that the SHIELD I results may provide supportive evidence on this population and recommended that the Company conduct an additional study to support a potential NDA submission. The FDA stated that the ongoing SHIELD II study could potentially serve as such a study. The FDA also recognized that D-PLEX100’s proposed indication is for the prevention of infection and has the potential for wide use.
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5309000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23865000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17236000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-238309000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">a.</td><td style="text-align: justify">Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2023	pypd	Estimated Useful Lives Description EstimatedUsefulLivesDescription	Over the shorter of the term of the lease or its useful life
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	83000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	738000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	542000	usd
CY2023	pypd	Received Total Amount ReceivedTotalAmount	7290000	usd
CY2023Q4	us-gaap	Royalty Guarantees Commitments Amount RoyaltyGuaranteesCommitmentsAmount	4888000	usd
CY2023	pypd	Nonroyalty Bearing Grants Amount NonroyaltyBearingGrantsAmount	1675000	usd
CY2023	pypd	Out Of Received Amount OutOfReceivedAmount	97000	usd
CY2023	pypd	Nonroyalty Bearing Grants NonroyaltyBearingGrants	727000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	0	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	12000	usd
CY2023Q4	pypd	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2023	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0.75in"></td><td style="width: 0.25in">r.</td><td style="text-align: justify">Revenue Recognition:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company recognizes revenue from contracts with customers under ASC No. 606, “<i>Revenue from Contracts with Customers</i>”. Accordingly, the Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">At contract inception, the Company assesses the goods or services agreed upon within each contract and assesses whether each good or service is distinct to determine the performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">On August 2, 2022, the Company entered into a license, distribution and supply agreement (the “Agreement”) with Mercury Pharma Group Limited, under the trade name Advanz Pharma Holdings (the “Customer”), with respect to the Company’s product, the D-PLEX<sub>100</sub> (the “Product”), for the prevention of (i) post abdominal surgery incisional infection; and/or (ii) post cardiac surgery sternal infection.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The term of the Agreement is until the later of December 31, 2035, or 10 years after the first commercial sale of the Product. The Agreement can also be terminated by either party under certain limited circumstances. Pursuant to the Agreement, the Customer was granted an exclusive license to market, commercialize, and distribute the Product in the European Economic Area and in the United Kingdom. Under the Agreement, the Company will carry out all activities required to obtain marketing authorization in each territory, approving the commercial sale of the Product in that territory. Once marketing authorization will be granted in a territory, the Customer will be required to achieve minimum sales requirements for that territory.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Under the terms of the Agreement, the Company received a non-refundable, one-time payment of €2.5 million (approximately $2,548). The Company is also entitled to receive additional development-related milestones payments for a total of up to €23 million. In addition, the Company will be entitled to receive up to additional €87 million upon achievement of certain commercial sale milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company has concluded that the Agreement includes a single performance obligation. The Company has concluded that the license and development are not distinct from the manufacturing since the Customer could not use, consume, or sell the license and development services on their own or with resources readily available to the Customer because of the Company’s specialized knowledge and the associated manufacturing know-how and because currently, and in the foreseeable future, there are no other parties that could manufacture the Product. As such, the transaction price was fully allocated to the single performance obligation. Since it is not probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the milestone payments is resolved, the Company estimated the transaction price at €2.5 million (approximately $2,548).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">As of December 31, 2023, the Company has yet to satisfy its performance obligation under the Agreement and, therefore, no revenues were recognized. Accordingly, the upfront payment amount was classified as a long-term deferred revenue in the Company’s consolidated balance sheet as of December 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"> </p>
CY2023	pypd	Agreement Term AgreementTerm	P10Y
CY2023	pypd	Non Refundable Amount NonRefundableAmount	2500000	eur
CY2023	pypd	Non Refundable Amount NonRefundableAmount	2548000	usd
CY2023	pypd	Additional Developmentrelated Milestones Payments AdditionalDevelopmentrelatedMilestonesPayments	23000000	eur
CY2023	pypd	Additional Amount Of Commercial Sale Milestones AdditionalAmountOfCommercialSaleMilestones	87000000	eur
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2500000	eur
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2548000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">s.</td><td style="text-align: justify">Concentration of credit risks:</td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">Cash, cash equivalents, restricted cash and short-term deposits are deposited in major banks in Israel and in the United States of America. Such investments may be in excess of insured limits or not insured. Generally, cash and cash equivalents may be redeemed upon demand and, therefore, bear minimal risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in">The Company utilizes option and forward contracts to protect against the risk of overall changes in exchange rates. The derivative instruments hedge a portion of the Company’s non-dollar currency exposure. Counterparties to the Company’s derivative instruments are all major financial institutions.</p>
CY2023Q4	pypd	Monthly Deposits At A Rate monthlyDepositsAtARate	0.0833	pure
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	401000	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	537000	usd
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	547000	usd
CY2023	pypd	Matching Contributions Amounts MatchingContributionsAmounts	14000	usd
CY2022	pypd	Matching Contributions Amounts MatchingContributionsAmounts	30000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15418000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15222000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7797000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5975000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7621000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9247000	usd
CY2023	us-gaap	Depreciation Depreciation	1822000	usd
CY2022	us-gaap	Depreciation Depreciation	1721000	usd
CY2021	us-gaap	Depreciation Depreciation	1118000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16000	usd
CY2023Q4	us-gaap	Deposit Assets DepositAssets	209000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M14D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0845	pure
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1170000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	587000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	414000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	374000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	184000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1559000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	162000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1397000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1020000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	241000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	995000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1246000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	958000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1167000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	18000	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1971000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2429000	usd
CY2022Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	15000000	usd
CY2023	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.08	pure
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1000000	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	468000	usd
CY2023	us-gaap	Line Of Credit Facility Description LineOfCreditFacilityDescription	The proceeds allocation resulted in $2,380 allocated to the Second Tranche and $120 allocated to the warrants.
CY2023	pypd	Percentage Of Remaining Principal PercentageOfRemainingPrincipal	0.70	pure
CY2023Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.10	pure
CY2023	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.01	pure
CY2023	pypd	Percentage Of Incremental Pay PercentageOfIncrementalPay	0.03	pure
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1500000	usd
CY2023	pypd	Percentage Of Credit Line Denominated PercentageOfCreditLineDenominated	0.0925	pure
CY2023Q4	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.10	pure
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	1038000	usd
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	734000	usd
CY2023	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	1685000	usd
CY2022	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	1023000	usd
CY2023Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	127000	usd
CY2023Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	60000	usd
CY2023Q4	us-gaap	Other Additional Capital OtherAdditionalCapital	31000	usd
CY2023	pypd	Proceeds From Participation Payments ProceedsFromParticipationPayments	4888000	usd
CY2023Q4	pypd	Percentage Of Sales PercentageOfSales	0.03	pure
CY2023Q4	pypd	Percentage Of Grant Received PercentageOfGrantReceived	1	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-23348000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-38274000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-41197000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-448000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1154000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-1404000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-23796000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-39428000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-42601000	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	174490000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	40133000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34984000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	4044000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5376000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	292000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	490000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	207000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	157000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44676000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	41007000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	44338000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	40448000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	338000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	559000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	338000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	559000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	338000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	559000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.003	pure
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	129000	usd
CY2021Q3	pypd	Aggregate Offering Price AggregateOfferingPrice	45000000	usd
CY2023Q2	pypd	Aggregate Offering Price AggregateOfferingPrice	8707000	usd
CY2023	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	2328000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	92000	usd
CY2022	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	4423000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	222000	usd
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	561967	shares
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.6
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	6415000	usd
CY2023Q1	us-gaap	Other Ownership Interests Offering Costs OtherOwnershipInterestsOfferingCosts	665000	usd
CY2023Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	2106000	usd
CY2023Q2	pypd	Authorized Share Capital AuthorizedShareCapital	60000000	shares
CY2023Q2	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	1905000	usd
CY2023Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	201000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	345151	shares
CY2023Q3	pypd	Number Of Options NumberOfOptions	156667	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	67385	shares
CY2023Q1	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	23.07
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	562000	usd
CY2023Q1	pypd	Vested Option Amount VestedOptionAmount	307000	usd
CY2023Q2	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	17417	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	63000	usd
CY2023Q2	pypd	Vested Option Amount VestedOptionAmount	50000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.66
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	pypd	Expected Dividend Yield ExpectedDividendYield	0	pure
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3391000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4307000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4750000	usd
CY2023	pypd	Unrecognized Compensation Costs UnrecognizedCompensationCosts	4235000	usd
CY2023	pypd	Recognized Over Weighted Average Period RecognizedOverWeightedAveragePeriod	P2Y3M7D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16781	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	12030	shares
CY2021	us-gaap	Other Income OtherIncome	58000	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	782000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	799000	usd
CY2021	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	632000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	7088	shares
CY2023Q4	pypd	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7088	shares
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	1618000	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	1023000	usd
CY2023	us-gaap	Other Expenses OtherExpenses	93000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	316000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	26000	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1711000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1339000	usd
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	26000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	33000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	532000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	44000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	548000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	267000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	468000	usd
CY2023	pypd	Remeasurement Of Warrants RemeasurementOfWarrants	-201000	usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	570000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-929000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-540000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	544000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23865000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-39557000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-42601000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1404368	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	647556	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	624051	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	16.99
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	61.09
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	68.27
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	24066000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	39557000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	42601000	usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1421308	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	647556	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	624051	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.93
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	61.09
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	68.27
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	78544	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	96689	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	73809	shares
CY2023Q4	us-gaap	Deposits Assets DepositsAssets		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue		usd
CY2023	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
CY2022	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2022	pypd	Proceeds From Issuance Of Prefunded Warrants Net ProceedsFromIssuanceOfPrefundedWarrantsNet		usd
CY2021	pypd	Proceeds From Issuance Of Prefunded Warrants Net ProceedsFromIssuanceOfPrefundedWarrantsNet		usd
CY2023	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2021	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
CY2023	pypd	Property And Equipment Paid For In Prior Periods PropertyAndEquipmentPaidForInPriorPeriods		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022	pypd	Credit Line Derivative CreditLineDerivative		usd
CY2021	pypd	Credit Line Derivative CreditLineDerivative		usd
CY2022	pypd	Modification Of Warrants ModificationOfWarrants		usd
CY2021	pypd	Modification Of Warrants ModificationOfWarrants		usd
CY2021	us-gaap	Stock Issued1 StockIssued1		usd
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P12M
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense		usd
CY2022	pypd	Remeasurement Of Warrants RemeasurementOfWarrants		usd
CY2021	pypd	Remeasurement Of Warrants RemeasurementOfWarrants		usd
CY2023	us-gaap	Other Income OtherIncome		usd
CY2022	us-gaap	Other Income OtherIncome		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001611842

Files In Submission

Name	View Source	Status
0001213900-24-020424-index-headers.html	Edgar Link	pending
0001213900-24-020424-index.html	Edgar Link	pending
0001213900-24-020424.txt	Edgar Link	pending
0001213900-24-020424-xbrl.zip	Edgar Link	pending
ea0200588-20f_polypidltd.htm	Edgar Link	pending
ea0200588ex12-1_polypid.htm	Edgar Link	pending
ea0200588ex12-2_polypid.htm	Edgar Link	pending
ea0200588ex13-1_polypid.htm	Edgar Link	pending
ea0200588ex13-2_polypid.htm	Edgar Link	pending
ea0200588ex15-1_polypid.htm	Edgar Link	pending
ea0200588ex2-4_polypid.htm	Edgar Link	pending
ea0200588ex4-15_polypid.htm	Edgar Link	pending
ea0200588ex97-1_polypid.htm	Edgar Link	pending
ex4-15_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pypd-20231231.xsd	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ea0200588-20f_polypidltd_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
pypd-20231231_pre.xml	Edgar Link	unprocessable
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
pypd-20231231_cal.xml	Edgar Link	unprocessable
pypd-20231231_def.xml	Edgar Link	unprocessable
pypd-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PYPD
PolyPid Ltd Stock $pypd

2023 Q4 Form 20-F Financial Statement

#000121390024020424 Filed on March 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PYPD PolyPid Ltd Stock $pypd

2023 Q4 Form 20-F Financial Statement

#000121390024020424 Filed on March 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PYPD
PolyPid Ltd Stock $pypd